Quantitation of integrated proviral DNA in viral reservoirs

Current Opinion in HIV and AIDS

Volumn 8, Issue 2, 2013, Pages 100-105

  Graf, Erin H ^a   O'Doherty, Una ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

HIV latency; HIV reservoirs; integrated HIV DNA

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; GAG PROTEIN; VIRUS RNA;

ALU SEQUENCE; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; COCULTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; STANDARDIZATION; VIREMIA; VIRUS CULTURE; VIRUS DNA CELL DNA INTERACTION; VIRUS REPLICATION;

DNA, VIRAL; HIV; HIV INFECTIONS; HUMANS; PROVIRUSES; VIRAL LOAD; VIRUS INTEGRATION;

EID: 84873421734     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32835d8132     Document Type: Review

References (34)

1. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188.
2. Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: A global scientific strategy. Nat Rev Immunol 2012; 12:607-614.
3. Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012; 26:1261-1268.
4. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl AcadSci USA 1997; 94:13193-13197.
5. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 T cells. Nat Med 2003; 9:727-728.
6. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-1295.
7. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
8. Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 2011; 25:885-897.
9. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012; 37:377-388.
10. Brussel A, Sonigo P. Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J Virol 2003; 77:10119-10124.
11. O'Doherty U, Swiggard WJ, Jeyakumar D, et al. A sensitive, quantitative, assay for Human Immunodeficiency Virus type 1 integration. J Virol 2002; 76:10942-910950.
12. Butler SL, Hansen MST, Bushman FD. A quantitative assay for HIV DNA integration in vivo. Nat Med 2001; 7:631-634.
13. Liszewski MK, Yu JJ, O'Doherty U. Detecting HIV-1 integration by repetitivesampling Alu-gag PCR. Methods 2009; 47:254-260.
14. Graf EH, MexasF AM. Yu JJ, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV patients on and off HAART. PLoS Pathog 2011; 7:e1001300.
15. Yu JJ, Wu TL, Liszewski MK, et al. A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in anti-retroviral therapy treated patients. Virology 2008; 379:78-86.
16. Murray JM, McBride K, Boesecke C, et al. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS 2012; 26:543-550.
17. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
18. Mexas AM, Graf EH, Pace MJ, et al. Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials. AIDS 2012; 26:2295-2306.
19. Erikkson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013.
20. Mendoza D, Johnson SA, Peterson BA, et al. Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood 2012; 119:4645-4655.
21. Koelsch KK, Boesecke C, McBride K, et al. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS 2011; 25:2069-2078.
22. Azzoni L, Foulkes AS, Papasavvas E, et al. Pegylated interferon alfa-2a monotherapy results in suppression of HIV-1 replication and decreased cellassociated HIV DNA integration. J Infect Dis 2013; 207:213-222.
23. Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.
24. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010; 24:1598-1601.
25. Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: Role of patient characteristics and effect of therapy. Antivir Ther 2012; 17:1001-1009.
26. Trautmann L, Mbitikon-Kobo FM, Goulet JP, et al. Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood 2012; 120:3466-3477.
27. Goujard C, Emilie D, Roussillon C, et al. Continuous versus intermittent treatment strategies during primary HIV-1 infection: The randomized ANRS INTERPRIM Trial. AIDS 2012; 26:1895-1905.
28. Hamlyn E, Ewings FM, Porter K, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One 2012; 7:e43754.
29. Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): Effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 2012; 205:87-96.
30. Chun TW, Murray D, Justement JS, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011; 204:135-138.
31. Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202:1553-1561.
32. Koelsch KK, Liu L, Haubrich R, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 2008; 197:411-419.
33. Agosto LM, Liszewski MK, Mexas A, et al. Patients on HAART often have an excess of unintegrated HIV DNA: Implications for monitoring reservoirs. Virology 2011; 409:46-53.
34. Hoxie J, June CH. Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med 2012; 2:1-21.